X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (3860) 3860
Publication (519) 519
Newsletter (110) 110
Book Review (41) 41
Book Chapter (10) 10
Newspaper Article (10) 10
Conference Proceeding (6) 6
Magazine Article (2) 2
Dissertation (1) 1
Presentation (1) 1
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
temozolomide (3327) 3327
humans (2690) 2690
index medicus (2479) 2479
oncology (2102) 2102
glioblastoma (1587) 1587
chemotherapy (1461) 1461
female (1458) 1458
male (1425) 1425
dacarbazine - analogs & derivatives (1423) 1423
cancer (1324) 1324
middle aged (1166) 1166
radiotherapy (1110) 1110
brain neoplasms - drug therapy (1055) 1055
adult (1036) 1036
glioblastoma multiforme (995) 995
aged (983) 983
gliomas (843) 843
clinical neurology (802) 802
dacarbazine - administration & dosage (761) 761
tumors (750) 750
adjuvant temozolomide (734) 734
care and treatment (732) 732
glioblastoma - drug therapy (728) 728
treatment outcome (707) 707
animals (696) 696
survival (672) 672
medicine & public health (638) 638
glioma (636) 636
brain neoplasms - pathology (631) 631
malignant glioma (615) 615
cell line, tumor (599) 599
dacarbazine - therapeutic use (596) 596
brain tumors (549) 549
research (521) 521
antineoplastic combined chemotherapy protocols - therapeutic use (494) 494
analysis (490) 490
brain cancer (483) 483
glioma - drug therapy (478) 478
apoptosis (467) 467
glioblastoma - pathology (466) 466
antineoplastic agents, alkylating - therapeutic use (465) 465
surgery (460) 460
brain neoplasms - therapy (455) 455
mice (437) 437
neurology (436) 436
prognosis (409) 409
combined modality therapy (405) 405
drug therapy (404) 404
brain neoplasms - mortality (399) 399
health aspects (392) 392
bevacizumab (386) 386
therapy (379) 379
pharmacology & pharmacy (375) 375
radiation therapy (373) 373
dosage and administration (363) 363
disease-free survival (356) 356
phase-ii trial (351) 351
retrospective studies (349) 349
radiation-therapy (344) 344
trial (342) 342
antineoplastic agents (338) 338
antineoplastic agents, alkylating - administration & dosage (336) 336
brain (335) 335
phase-ii (332) 332
patients (331) 331
antimitotic agents (323) 323
cancer therapies (320) 320
glioblastoma - therapy (319) 319
radiation (319) 319
expression (315) 315
antineoplastic agents - therapeutic use (314) 314
brain neoplasms - radiotherapy (309) 309
dacarbazine - adverse effects (307) 307
clinical trials (305) 305
glioma - pathology (300) 300
magnetic resonance imaging (296) 296
survival analysis (294) 294
medical prognosis (289) 289
glioblastoma - mortality (286) 286
dacarbazine - pharmacology (281) 281
glioblastoma-multiforme (278) 278
young adult (278) 278
article (276) 276
newly-diagnosed glioblastoma (269) 269
aged, 80 and over (268) 268
concomitant (260) 260
adolescent (253) 253
neoplasm recurrence, local - drug therapy (250) 250
multiforme (247) 247
toxicity (244) 244
melanoma (242) 242
malignant gliomas (240) 240
glioblastoma - radiotherapy (235) 235
medical research (234) 234
antineoplastic agents - administration & dosage (232) 232
development and progression (231) 231
brain-tumors (230) 230
patient outcomes (230) 230
neurosciences (229) 229
medicine (227) 227
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3965) 3965
French (15) 15
German (4) 4
Spanish (4) 4
Polish (2) 2
Chinese (1) 1
Hungarian (1) 1
Japanese (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Clinical Cancer Research, ISSN 1078-0432, 01/2017, Volume 23, Issue 1, pp. 73 - 80
Purpose: Glioblastoma is the most malignant primary brain tumor, with a median survival of less than 2 years. More effective therapeutic approaches are needed... 
STEM-CELLS | ONCOLOGY | POTASSIUM CHANNELS | GASTRIC-CANCER | GLIOMA | CARDIAC-ARRHYTHMIA | PROLONGATION | SECRETION | TUMORS | K+ CHANNELS | TEMOZOLOMIDE | Drugs | Brain | Brain tumors | Glioblastoma | Data processing | Gene expression | Patients | Survival | Inhibitors | DNA microarrays | Experimental design | Human performance | Xenografts | Cancer | Biomarkers | K+ channels | HERG | Cancer stem-like cells
Journal Article
Cancer, ISSN 0008-543X, 10/2011, Volume 117, Issue 20, pp. 4617 - 4622
BACKGROUND: Patients with metastatic poorly differentiated endocrine carcinoma (PDEC) usually have a short survival. The chemotherapy combination of cisplatin... 
second‐line and temozolomide | chemotherapy | neuroendocrine cancer | PDEC | second-line and temozolomide | TRACT | PHASE-II TRIAL | ETOPOSIDE | NEUROENDOCRINE TUMORS | CISPLATIN | ONCOLOGY | SMALL-CELL CARCINOMA | Capecitabine | Humans | Middle Aged | DNA Repair Enzymes - genetics | Male | Antineoplastic Agents, Alkylating - administration & dosage | DNA Repair - genetics | Promoter Regions, Genetic - genetics | Bevacizumab | Cisplatin - administration & dosage | Antibodies, Monoclonal, Humanized - administration & dosage | Fluorouracil - administration & dosage | Tumor Suppressor Proteins - genetics | Dacarbazine - analogs & derivatives | Adult | Female | Carcinoma, Neuroendocrine - chemistry | Retrospective Studies | Dacarbazine - administration & dosage | Drug Administration Schedule | Fluorouracil - analogs & derivatives | Biomarkers, Tumor - analysis | Carcinoma, Neuroendocrine - drug therapy | Deoxycytidine - administration & dosage | Kaplan-Meier Estimate | Carcinoma, Neuroendocrine - genetics | Etoposide - administration & dosage | Treatment Outcome | DNA Methylation - genetics | Disease Progression | Disease-Free Survival | DNA Modification Methylases - genetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Carcinoma, Neuroendocrine - pathology | Aged | Deoxycytidine - analogs & derivatives | Salvage Therapy - methods | Endocrine gland cancer | Care and treatment | Dosage and administration | Temozolomide | Research | Carcinoma | Medical treatment | Medical services | Etoposide | Patients | Survival | Cisplatin | Metastases | Chemotherapy | Methylation | Cancer | temozolomide | second-line | Medical and Health Sciences | Medicin och hälsovetenskap | MEDICIN | MEDICINE
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 01/2017, Volume 23, Issue 2, pp. 523 - 535
Purpose: PARP inhibitors (PARPi) are a novel class of small molecule therapeutics for small cell lung cancer (SCLC). Identification of predictors of response... 
BREAST-CANCER | INACTIVATION | TRIAL | HOMOLOGOUS RECOMBINATION REPAIR | DRUG-SENSITIVITY | DNA-DAMAGING AGENTS | ONCOLOGY | ABT-888 | PHASE-II | POLY(ADP-RIBOSE) POLYMERASE INHIBITOR | BMN 673 | Piperazines - administration & dosage | Dacarbazine - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Phthalazines - administration & dosage | Humans | Etoposide - administration & dosage | Small Cell Lung Carcinoma - genetics | Small Cell Lung Carcinoma - drug therapy | Indoles - administration & dosage | Poly (ADP-Ribose) Polymerase-1 - antagonists & inhibitors | Cisplatin - administration & dosage | Poly(ADP-ribose) Polymerase Inhibitors - administration & dosage | Drug Synergism | Xenograft Model Antitumor Assays | Small Cell Lung Carcinoma - pathology | Animals | Benzimidazoles - administration & dosage | Dacarbazine - analogs & derivatives | Cell Line, Tumor | Mice | Gene Expression Regulation, Neoplastic - drug effects | Genomics - methods | Nuclear Proteins - genetics | Poly (ADP-Ribose) Polymerase-1 - genetics | Immunohistochemistry | Therapy | Transcription | Lung cancer | Immunoblotting | Single-nucleotide polymorphism | Xenografts | CRISPR | Effectiveness | Small cell lung carcinoma | Etoposide | Poly(ADP-ribose) polymerase | Gene expression | Cisplatin | Scars | Inhibitors | Experimental design | Correlation analysis | Cell lines | Biomarkers | In vivo methods and tests | Temozolomide | Viability | Combinatorial analysis | Cancer | SLFN11 | small cell lung cancer | biomarker | PARP inhibition | patient-derived xenografts
Journal Article
Journal Article
Journal of the National Cancer Institute, ISSN 0027-8874, 12/2002, Volume 94, Issue 24, pp. 1883 - 1888
The prescribed dose of anticancer agents is most commonly calculated using body surface area as the only independent variable, and it has been shown that this... 
TOPOISOMERASE-I INHIBITOR | INTRAVENOUS CISPLATIN | DOSE-ESCALATION | ADVANCED SOLID TUMORS | ONCOLOGY | ORAL TOPOTECAN | MATRIX-METALLOPROTEINASE INHIBITOR | SCHEDULE | CLINICAL PHARMACOKINETICS | PHASE-I | CREMOPHOR EL | Cytosine - analogs & derivatives | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Drugs, Investigational - pharmacokinetics | Cytosine - administration & dosage | Male | Paclitaxel - pharmacokinetics | Antineoplastic Agents - administration & dosage | Dose-Response Relationship, Drug | Fluorouracil - administration & dosage | Uracil - administration & dosage | Dacarbazine - analogs & derivatives | Adult | Dacarbazine - pharmacokinetics | Dioxolanes - pharmacokinetics | Female | Antineoplastic Agents - pharmacokinetics | Retrospective Studies | Body Surface Area | Paclitaxel - administration & dosage | Dacarbazine - administration & dosage | Cytosine - pharmacokinetics | Drug Administration Schedule | Docosahexaenoic Acids - administration & dosage | Docosahexaenoic Acids - pharmacokinetics | Drugs, Investigational - administration & dosage | Dioxolanes - administration & dosage | Infusions, Intravenous | Temozolomide | Fluorouracil - pharmacokinetics | Uracil - pharmacokinetics | Clinical Trials, Phase I as Topic | Uracil - analogs & derivatives | Antimitotic agents | Drug metabolism | Dosage and administration | Testolactone | Antineoplastic agents | Analysis
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 11/2017, Volume 23, Issue 21, pp. 6441 - 6449
Purpose: Anti-GD2 mAbs, acting via antibody-dependent cell-mediated cytotoxicity, may enhance the effects of chemotherapy. This pilot trial investigated a... 
INTERLEUKIN-2 | MELANOMA | SOLID TUMORS | REFRACTORY NEUROBLASTOMA | ONCOLOGY | PHASE-I TRIAL | CYCLOPHOSPHAMIDE | IMMUNOTHERAPY | RECURRENT | CELLULAR CYTOTOXICITY | PLUS | Drug-Related Side Effects and Adverse Reactions - blood | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Neuroblastoma - blood | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Child, Preschool | Neoplasm Recurrence, Local - drug therapy | Infant | Male | Drug-Related Side Effects and Adverse Reactions - pathology | Neoplasm Recurrence, Local - pathology | Antibodies, Monoclonal, Humanized - administration & dosage | Antibodies, Monoclonal, Humanized - pharmacokinetics | Dacarbazine - analogs & derivatives | Killer Cells, Natural - immunology | Camptothecin - administration & dosage | Female | Child | Neoplasm Recurrence, Local - blood | Neuroblastoma - pathology | Camptothecin - analogs & derivatives | Antibodies, Monoclonal, Humanized - adverse effects | Dacarbazine - administration & dosage | Gangliosides - antagonists & inhibitors | Interleukin-2 Receptor alpha Subunit - blood | Carboplatin - administration & dosage | Etoposide - administration & dosage | Treatment Outcome | Combined Modality Therapy | Cell- and Tissue-Based Therapy | Gangliosides - immunology | Disease-Free Survival | Ifosfamide - administration & dosage | Neuroblastoma - drug therapy | Adolescent | Topotecan - administration & dosage | Drug-Related Side Effects and Adverse Reactions - classification | Interleukin-2 - blood | Toxicity | Cytotoxicity | Malignancy | Neuroblastoma | Cerebrospinal fluid | Pain | Interleukin 2 | Surgery | Myelosuppression | Children | Natural killer cells | Antibody-dependent cell-mediated cytotoxicity | Thrombocytopenia | Immune response | Cytokines | Ifosfamide | Granulocyte-macrophage colony-stimulating factor | Hypersensitivity | Etoposide | Pharmacology | Patients | Irinotecan | Cyclophosphamide | Chemotherapy | Experimental design | Monoclonal antibodies | Carboplatin | Temozolomide | Pharmacokinetics | Cancer | Index Medicus
Journal Article
International Journal of Radiation Oncology, Biology, Physics, ISSN 0360-3016, 2012, Volume 82, Issue 1, pp. 58 - 66
Purpose To determine the safety of the addition of bevacizumab to standard radiation therapy and daily temozolomide for newly diagnosed glioblastoma multiforme... 
Radiology | Hematology, Oncology and Palliative Medicine | Radiation therapy | Temozolomide | Glioblastoma multiforme | Bevacizumab | PLUS IRINOTECAN | VEGF | PHASE-II | CANCER | ADJUVANT TEMOZOLOMIDE | MALIGNANT GLIOMA | TRIAL | PSEUDOPROGRESSION | ONCOLOGY | CONCOMITANT | RADIOTHERAPY | RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING | Dacarbazine - adverse effects | Glucocorticoids - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Injections, Intravenous | Humans | Middle Aged | Brain Neoplasms - pathology | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Antineoplastic Agents, Alkylating - administration & dosage | Young Adult | Angiogenesis Inhibitors - administration & dosage | Antibodies, Monoclonal, Humanized - administration & dosage | Dacarbazine - analogs & derivatives | Aged, 80 and over | Adult | Camptothecin - administration & dosage | Dose Fractionation | Female | Angiogenesis Inhibitors - adverse effects | Camptothecin - analogs & derivatives | Antibodies, Monoclonal, Humanized - adverse effects | Camptothecin - adverse effects | Chemoradiotherapy - methods | Dacarbazine - administration & dosage | Dexamethasone - administration & dosage | Drug Administration Schedule | Tumor Burden | Glioblastoma - therapy | Magnetic Resonance Imaging | Glioblastoma - pathology | Brain Neoplasms - therapy | Craniotomy | Aged | Antineoplastic Agents, Alkylating - adverse effects | Angiogenesis inhibitors | Radiotherapy | Nuclear radiation | Standards | temozolomide | glioblastoma multiforme | Toxicity | Lung | Central nervous system | Radiation | Wounds | Adjuvants | Fatigue | Hemorrhage | Irinotecan | Pancytopenia | Dehiscence | Rectum | intervention | surgery | Index Medicus | GLIOMAS | SURGERY | PATIENTS | HEMORRHAGE | RECTUM | FATIGUE | PERFORMANCE | EMBOLI | STANDARDS | CENTRAL NERVOUS SYSTEM | RADIATION DOSES | TOXICITY | WOUNDS | ADMINISTRATIVE PROCEDURES | RADIOLOGY AND NUCLEAR MEDICINE | PERFORATION
Journal Article
Journal Article
by Weller, Michael and Butowski, Nicholas and Tran, David D and Recht, Lawrence and Recht, Lawrence D and Lim, Michael and Hirte, Hal and Ashby, Lynn and Mechtler, Laszlo and Goldlust, Samuel and Goldlust, Samuel A and Iwamoto, Fabio and Drappatz, Jan and O'Rourke, James and O'Rourke, Donald M and Wong, Mark and Hamilton, Mark G and Hamilton, Mark and Finocchiaro, Gaetano and Perry, James and Wick, Wolfgang and Green, Jennifer and He, Yi and Turner, Christopher D and Yellin, Michael J and Keler, Tibor and Davis, Thomas A and Stupp, Roger and Sampson, John H and Campian, Jian and Becker, Kevin and Barnett, Gene and Nicholas, Garth and Desjardins, Annick and Benkers, Tara and Wagle, Naveed and Groves, Morris and Kesari, Santosh and Horvath, Zsolt and Merrell, Ryan and Curry, Richard and Schuster, David and Mrugala, Maciej and Jensen, Randy and Trusheim, John and Lesser, Glenn and Belanger, Karl and Sloan, Andrew and Purow, Benjamin and Fink, Karen and Raizer, Jeffrey and Schulder, Michael and Nair, Suresh and Peak, Scott and Brandes, Alba and Mohile, Nimish and Landolfi, Joseph and Olson, Jon and Jennens, Ross and DeSouza, Paul and Robinson, Bridget and Crittenden, Marka and Shih, Kent and Flowers, Alexandra and Ong, Shirley and Connelly, Jennifer and Hadjipanayis, Costas and Giglio, Pierre and Mott, Frank and Mathieu, David and Lessard, Nathalie and Sepulveda, Sanchez Juan and Lövey, József and Wheeler, Helen and Inglis, Po-Ling and Hardie, Claire and Bota, Daniela and Lesniak, Maciej and Portnow, Jana and Frankel, Bruce and Junck, Larry and Thompson, Reid and Berk, Lawrence and McGhie, John and Macdonald, David and Saran, Frank and Soffietti, Riccardo and Blumenthal, Deborah and André de, Sá Barreto Costa Marcos and Nowak, Anna and Singhal, Nimit and Hottinger, Andreas and Schmid, Andrea and Srkalovic, Gordan and Baskin, David and Fadul, Camilo and Nabors, Louis and LaRocca, Renato and Villano, John and Paleologos, Nina and ... and ACT IV Trial Investigators and ACT IV trial investigators
The Lancet Oncology, ISSN 1470-2045, 10/2017, Volume 18, Issue 10, pp. 1373 - 1385
Rindopepimut (also known as CDX-110), a vaccine targeting the deletion mutation EGFRvIII, consists of an EGFRvIII-specific peptide conjugated to keyhole limpet... 
GLIOMAS | ONCOLOGY | RECURSIVE PARTITIONING ANALYSIS | GROWTH-FACTOR | RADIOTHERAPY | CANCER | PEPTIDE | ADJUVANT TEMOZOLOMIDE | Dacarbazine - adverse effects | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Follow-Up Studies | Humans | Middle Aged | Brain Neoplasms - pathology | ErbB Receptors - genetics | Gene Expression Regulation, Neoplastic | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Patient Selection | Dose-Response Relationship, Drug | Young Adult | Glioblastoma - genetics | Time Factors | Dacarbazine - analogs & derivatives | Adult | Female | Vaccines, Subunit - adverse effects | Brain Neoplasms - mortality | Dacarbazine - administration & dosage | Double-Blind Method | Drug Administration Schedule | Cancer Vaccines - administration & dosage | Kaplan-Meier Estimate | Proportional Hazards Models | Brain Neoplasms - genetics | Cancer Vaccines - adverse effects | Treatment Outcome | Brain Neoplasms - drug therapy | Disease-Free Survival | Internationality | Vaccines, Subunit - administration & dosage | Glioblastoma - pathology | Survival Analysis | Aged | Temozolomide | Glioblastoma - drug therapy | Glioblastoma - mortality | Antimitotic agents | Clinical trials | Care and treatment | Product development | Antineoplastic agents | Glioblastoma multiforme | Analysis
Journal Article
International Journal of Cancer, ISSN 0020-7136, 01/2016, Volume 138, Issue 1, pp. 187 - 194
Glioblastoma is the most aggressive primary central nervous system malignancy with a poor prognosis in patients. Despite the need for better treatments against... 
anti‐PD‐1 | glioblastoma | IL‐15 superagonist | ALT‐803 | IL-15 superagonist | ALT-803 | anti-PD-1 | GLIOMAS | CANCER | RADIATION | CD8(+) T-CELLS | TEMOZOLOMIDE | ONCOLOGY | IMMUNOTHERAPY | IMMUNOSUPPRESSION | INTERLEUKIN-15 | BLOCKADE | EXPRESSION | T-Lymphocyte Subsets - immunology | Humans | Radiosurgery | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Central Nervous System Neoplasms - immunology | T-Lymphocyte Subsets - drug effects | Immunotherapy | Female | Glioblastoma - metabolism | Lymphocytes, Tumor-Infiltrating - metabolism | Antineoplastic Agents - pharmacology | Disease Models, Animal | Central Nervous System Neoplasms - metabolism | Antibodies, Monoclonal - pharmacology | Programmed Cell Death 1 Receptor - metabolism | Central Nervous System Neoplasms - therapy | Glioblastoma - therapy | Xenograft Model Antitumor Assays | Central Nervous System Neoplasms - pathology | Animals | Interleukin-15 - agonists | Glioblastoma - immunology | T-Lymphocyte Subsets - metabolism | Glioblastoma - pathology | Cell Line, Tumor | Immunologic Memory | Mice | Proteins - pharmacology | Glioblastoma - mortality | Central Nervous System Neoplasms - mortality | Lymphocytes, Tumor-Infiltrating - immunology | Killer cells | Immune response | Interleukins | Analysis | Health aspects | Glioblastoma multiforme | Cytokines | Medical prognosis | Immune system
Journal Article